Investigating nanofat injection and conditioned medium derived from stem cells in the treatment of androgenic alopecia
Phase 1
Not yet recruiting
- Conditions
- Hair loss.Nonscarring hair loss, unspecifiedL65.9
- Registration Number
- IRCT20200127046282N34
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Age between 18-60
Patients who do not want to take or are allergic to minoxidil
Exclusion Criteria
Individuals who have used any product or medication during the previous 6 months that may affect hair growth
Pregnancy and breastfeeding
History of cancer
People with Mental Disorders
Active infection of the scalp
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie nanofat and Wharton jelly MSC-CM effects in androgenic alopecia?
How does nanofat plus MSC-CM compare to minoxidil or finasteride in treating androgenic alopecia?
Which biomarkers correlate with response to nanofat and MSC-CM in androgenic alopecia patients?
What are the safety profiles of intradermal nanofat and MSC-CM in phase I alopecia trials?
Are there combination therapies with nanofat and MSC-CM for androgenetic alopecia beyond hair restoration?